MedTrace Logo

PET With [18F]HX4 in Head and Neck Cancer

NCT01347281 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2017-01-30

No results posted yet for this study

Summary

The aim of this study is to (i) Determine if tumor hypoxia can be accurately visualised with \[18F\] HX4 PET imaging in head and neck tumors (ii) correlate the \[18F\] HX4 PET images with blood and tissue markers and (iii) investigate the quality and optimal timing of \[18F\] HX4 PET imaging (iv) compare \[18F\] HX4 PET uptake with \[18F\] FDG PET uptake before and after treatment.

Conditions

  • Cancer of the Head and Neck

Interventions

PROCEDURE

Injection of [18F]HX4

Injection of \[18F\]HX4 before treatment (baseline) and after radiotherapy with 20 +/-4 Gy: \[18F\]HX4 PET scans; 444 MBq (12 mCi) \[18F\]HX4 administrated via a bolus IV injection. Image acquisition: static scan at 240 min p.i. Venous blood sampling: before injection of \[18F\]HX4 (blood hypoxia markers) Follow-up (3 months after treatment): \[18F\]FDG PET in treatment position

Sponsors & Collaborators

  • Maastricht Radiation Oncology

    lead OTHER

Principal Investigators

  • Philppe Lambin, Prof. Dr. · Maastro Clinic, The Netherlands

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2015-08-31
Completion
2015-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01347281 on ClinicalTrials.gov